NTPDase1

NTPDase8, encoded by ENTPD8, hydrolyzes nucleoside triphosphates and diphosphates to monophosphates, thereby shaping extracellular nucleotide availability and purinergic signaling^[1][2]. Mechanistically, plasma-membrane NTPDases 1, 2, 3, and 8 hydrolyze ATP and UTP in the micromolar range, but NTPDase8 differs by generating transient ADP accumulation, which may support short-lived ADP-receptor activation compared with NTPDase1^[3]. In liver, cloned human and rat NTPDase8 matched the canalicular ecto-ATPase/ATPDase, showed high bile-canalicular activity, and accounted for the major hepatic NTPDase activity^[4]. Therefore, its canalicular localization supports experimental studies of bile secretion, nucleoside salvage, and liver extracellular nucleotide metabolism^[4]. In zebrafish, entpd8 appears with distinct NTPDase-family expression profiles in brain, liver, and heart, supporting comparative models of tissue-specific nucleotide hydrolysis^[5]. In disease models, ENTPD8 was downregulated in pancreatic cancer tissues and linked to weakened CTP dephosphorylation and reduced cytidine formation^[6]. In hepatocellular carcinoma, ENTPD8 overexpression inhibited proliferation, invasion, and migration and enhanced anti-PD-L1 efficacy through miR-214-5p modulation^[7]. For inhibitor applications, sulfamoyl benzamide derivatives identified 2-chloro-5-(N-cyclopropylsulfamoyl)benzoic acid as a selective NTPDase8 inhibitor, supporting isoform-focused enzymology and purinergic-signaling assays^[8].